Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay. The investigators aimed at assessing whether the widely used heparin anti-Xa assay can quantify the apixaban, rivaroxaban, fondaparinux and danaparoid levels.
Study Type
OBSERVATIONAL
Enrollment
2,100
Estimated anticoagulant level (conversion factor x anti-Xa activity)
Nantes University Hospital
Nantes, Loire-Atlantique, France
RECRUITINGAgreement between measured and estimated levels of each factor-Xa inhibitor
An estimated anticoagulant level between 80 and 120% of the value obtained by the reference method ("specific assay") will be deemed clinically acceptable, i.e. the patient's management would have been the same.
Time frame: 2 years
Evaluation of the performance of the estimated anticoagulant level method by an inter-laboratory comparison program
Time frame: 2 years
Cost comparison (estimated anticoagulant level method versus specific dosage)
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.